home / stock / morf / morf quote
Last: | $ |
---|---|
Change Percent: | -11.12% |
Open: | $17.83 |
Close: | $17.50 |
High: | $18.485 |
Low: | $16.35 |
Volume: | 387,973 |
Last Trade Date Time: | 02/12/2020 04:42:28 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $17.83 | $17.50 | $18.485 | $16.35 | 387,973 | 02-12-2020 |
$ | $19.79 | $19.69 | $20.12 | $19.20 | 128,988 | 02-11-2020 |
$ | $19.36 | $19.90 | $19.90 | $19.29 | 33,069 | 02-10-2020 |
$ | $19.85 | $19.34 | $20.78 | $17.6211 | 1,180,980 | 02-07-2020 |
$ | $19.76 | $20.15 | $20.315 | $19.66 | 47,174 | 02-06-2020 |
$ | $19.99 | $19.84 | $20.20 | $19.45 | 75,335 | 02-05-2020 |
$ | $20.11 | $20.00 | $20.5055 | $19.85 | 65,484 | 02-04-2020 |
$ | $20.03 | $19.92 | $20.95 | $19.27 | 97,474 | 02-03-2020 |
$ | $19.76 | $20.10 | $20.455 | $19.09 | 95,604 | 01-31-2020 |
$ | $20.61 | $19.95 | $21.22 | $19.90 | 124,556 | 01-30-2020 |
$ | $20.76 | $20.85 | $21.45 | $20.57 | 162,860 | 01-29-2020 |
$ | $19.36 | $20.76 | $22.69 | $19.35 | 148,328 | 01-28-2020 |
$ | $18.66 | $19.36 | $20.15 | $18.15 | 138,066 | 01-27-2020 |
$ | $18.66 | $18.96 | $19.52 | $18.54 | 65,004 | 01-24-2020 |
$ | $19.13 | $18.86 | $19.55 | $17.90 | 63,507 | 01-23-2020 |
$ | $19.83 | $19.43 | $20.05 | $18.96 | 78,368 | 01-22-2020 |
$ | $19.51 | $19.87 | $20.50 | $18.51 | 73,396 | 01-21-2020 |
$ | $20.28 | $19.69 | $20.86 | $19.07 | 71,009 | 01-20-2020 |
$ | $20.28 | $19.69 | $20.86 | $19.07 | 71,009 | 01-17-2020 |
$ | $19.88 | $20.14 | $20.50 | $19.80 | 72,767 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. If yo...
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside c...
-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease...